Excellent point Bear! This once again supports the multifacited impacts of apabetalone and hence possible applications in multiple indications.

To me, and this has been noted before, the central point is that Pfizer has studied this molecule (apabetalone) and is curious enough to conduct their own clinical trial. One could speculate that this may be the tip of the iceburg in terms of Pfizer developing a larger interest in apabetalone, RVX and/or Zenith.

I am also speculating based on Pfizer's interest they are not the only BP studying apabetalone.

For me, other than the recently published academic papers requarding retinal and a rare MD, the Pfizer project is the first actual, tangiblle evidence of hands on evidence and interest by BP. I find this very exciting.

Also, I assume that Pfizer has to pay royalties to RVX if they go to market with this FA application. Hope that is correct.

GLTA

Toinv